No abstract

Rasburicase (Fasturtec), a recombinant urate oxidase, is highly effective in preventing and treating hyperuricemia in children with hematologic malignancies. We conducted a prospective, multicenter observational study in 174 patients at 8 pediatric hemato-oncology centers to establish whether the SFCE (Société Française de Lutte contre les Cancers et Leucémies de l'Enfant et de l'Adolescent) recommendations for the use of rasburicase in the management of pediatric patients at risk of tumor lysis syndrome (TLS) are valid in routine clinical practice. Patients were classified as being at high or low risk of TLS according to the Children's Oncology Group criteria and were treated in accordance with the SFCE recommendations. The primary end point was the number of patients requiring a higher dose of rasburicase or a longer duration of treatment than advised in the SFCE recommendations. Of the 135 patients at high risk of TLS, 27 patients received a higher dose and 35 patients received a longer duration of treatment. Some patients received treatment with rasburicase for less than the recommended duration (median 4 d for high-risk patients). One patient required hemodialysis. Only minor adjustments to the SFCE recommendations were required to ensure the optimal use of rasburicase in pediatric patients at risk of TLS.

No abstract

as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed (PSR) BRCA-mutated OC who are in response to platinum-based chemotherapy (PBC). In addition, film-coated tablets were approved in the EU in May 2018 for PSR-OC regardless of BRCA status, and in June 2019 for adult patients with advanced BRCA-mutated OC who are in response to first-line PBC. So far, only limited data on real-world maintenance monotherapy with olaparib are available. We evaluated HRQoL during olaparib maintenance in this observational study. Methods:The German prospective non-interventional study C-PATROL (NCT02503436) collects routine clinical and patient-reported outcome (PRO) data of BRCA-mutated PSR OC patients treated with olaparib according to label. In total, 278 patients were enrolled in the study until 30 Sep 2019 (end of recruitment). In the 4 th interim analysis (cut-off date: 22/04/20), HRQoL was evaluated during the 1 st year of olaparib maintenance therapy using the FACT-Ovarian and FACIT-Fatigue questionnaires.Results: 271 BRCAm PSR OC patients treated with olaparib were analyzed (median age: 60 yrs; ECOG 1: 93%; !2 relapses: 32%; !3 prior platinum chemotherapies: 34%). More than 80% have provided questionnaires at baseline and month 3; and >60%, 55% and 45% at month 6, 9 and 12, respectively, until data cut-off. The FACT-O total score as well as trial outcome index (TOI) remained consistent over time (mean scores

The syndrome of heparin-induced thrombocytopenia (HIT), with an incidence of 0.2-0.5% in patients exposed to heparin for more than 4 days, is produced by an immune alteration with the formation of antibodies against the heparin platelet factor 4 complex. It presents a wide spectrum of clinical manifestations, the most frequent of which are thrombocytopenia, thrombotic arterial-venous phenomena, and cutaneous necrosis. Up to the present, lepiridin, recently suspended, and argatroban (direct thrombin inhibitors) have been the approved medicines normally used in treatment, administered in parenteral form. Dabigatran, a new anticoagulant medicine that is a direct and reversible thrombin inhibitor, could theoretically be a medicine employed in treating HIT. According to the bibliography consulted we are presenting the first case of HIT treated with dabigatran in the medical literature.